In a related matter, the U.S. Food and Drug Administration (FDA) is requiring manufacturers to include a general warning in the drug labeling of all approved testosterone products about the risk of blood clots in the veins, encompassing the risk of injuries such as deep vein thrombosis and pulmonary embolism. The FDA previously required warnings about the possible consequence of polycythemia, an abnormal increase in the number of red blood cells, that sometimes occurs with testosterone treatment. Due to increased reports of blood clot injuries unrelated to polycythemia, the FDA is requiring a change to drug labeling of all testosterone products to provide a more general warning regarding venous blood clots and to ensure this risk is described consistently in the labeling of all approved testosterone products. Additionally, the FDA continues to investigate the possible risk of stroke, heart attack, and death in patients taking testosterone products.
As stated above Beasley Allen lawyers are currently representing men who have been injured by their use of testosterone drugs. If you have any questions about the MDL or any aspect of the testosterone litigation, contact Matt Teague to discuss this litigation. Matt can be contacted at 800-898-2034 or by email at Matt.Teague@beasleyallen.com.
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.